Mesenchymal Stem Cells Market Analysis
Mesenchymal Stem Cells Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Mesenchymal stem cells, also known as Mesenchymal Stromal Cells (MSCs), are adult, fibroblast-like multipotent cells that can differentiate and mature into tissues of mesodermal origin such as adipocytes, chondroblasts, and osteoblasts. Mesenchymal stem cells were isolated first time from the bone marrow and later from various sources such as cord cells, adipose tissue, and molar cells. MSCs in terms of size, are smaller and are quite difficult to observe in histological sections. A group of mesenchymal stem cells are called as mesenchyme and is widely distributed in the body. Mesenchymal cells can multiply in numbers of specialized cells and they can grow in-vitro or in-vivo condition.
The mesenchymal stem cells play an important role within an organism for suppression of immune cells activation, increase the number of newer cells, reduce cell death or cell damage in the body, and secretion of both neurotrophic and angiogenic factors, which are responsible for stabilizing the extracellular matrix, when transplanted to the brain, this cells promote the reduction of free radical levels and enhance synaptic connections of damaged neurons, and increases the myelination of axons. The mesenchymal cells are also able to replace and repair any damaged blood vessel in the cerebrum brain.
Rise in prevalence of osteoporosis and increase in cancer incidences are expected to support the global market growth
MSCs have the ability to grow bone tissues through the bone surface to form new bone, which in turn has the potency to treat osteoporosis. According to the National Institute of Health (NIH), in 2015, the U.S. accounted for around 53 million people suffering from osteoporosis or at a high risk due to low bone mass.
According to Osteoporosis Canada, around 1 in 5 men and 1 in 3 women suffer from osteoporotic fracture during their lifetime, whereas osteoporosis causes around 70-90% of 30,000 hip fractures yearly; the annual cost to Canada for treating osteoporosis was around US$ 4.0 billion in the year 2012, which is expected to rise in the upcoming years. Furthermore, according to the International Osteoporosis Foundation (IOF), annually around 9.0 million people worldwide are suffering from osteoporosis fractures. The aforementioned factors are expected to bolster the Mesenchymal stem cells market growth over the forecast period.
North America and Asia Pacific are expected to hold large market shares followed by Europe due to the rapid growth in technological innovations, high disposable incomes, and the well-equipped healthcare centers, which will lead to the growth and development of MSCs market. The implantation of new mesenchymal stem cells in cancer patients is expected to enhance the growth of MSCs market.
As per the World Health Organization (WHO) 2018 Factsheet, Cancer is the second leading cause of death globally, and it caused around 9.6 million deaths in 2018 globally. According to the European Journal of Cancer, Europe witnessed over 3.9 million cases of cancer and around 1.9 million deaths from cancer in the year 2018. Whereas, according to National Center for Biotechnology Information (NCBI), in Asia Pacific, breast cancer in females was found to be around 18.0% in the year 2012 and it was the fourth most cause for around 9% death due to cancer in the region.
Mesenchymal Stem Cells Market Players
Key players in the market are focusing on inorganic growth strategies such as acquisition and collaboration in order to expand its research and development activities and geographical presence. For instance in February 2019 Pluristem Therapeutics has collaborated with the NASA's Ames Research Center to evaluate the potential of Pluristem's PLX cell therapies in preventing and treating medical conditions caused during space missions. During space mission astronauts are exposed to a challenging environment that includes radiation and microgravity, leading to muscle and bone loss as well as other potentially serious medical conditions. The collaboration will explore the possibility that PLX placenta-based cell therapy products can address these and other persistent negative effects of space travel on the human body.
In February 2019, BrainStorm Cell Therapeutics Inc. announced to expand its clinical trial facility with Cleveland Clinic as the first U.S. clinical site contracted for a planned Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous Mesenchymal Stem Cell (MSC-NTF) cells in participants with progressive Multiple Sclerosis (MS).
Moreover most of the key players are focusing on new product launch in the global mesenchymal stem cell market. For instance in February 2019, Cytonus Therapeutics has developed Cargocytes a first-of-its-kind, controllable, cell-based platform technology for delivery of biologics. Cargocytes are engineered allogenic cell lines that can carry a variety of small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses. As a platform technology, cargocyte has many therapeutic applications and will be commercialized through a blend of internal and partnered programs.
Some of the key market players identified across the value chain of mesenchymal stem cells market are, Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.
Mesenchymal Stem Cells Market Taxonomy
On the basis of product type, the global Mesenchymal Stem Cells Market is segmented into:
On the basis of application, the global Mesenchymal Stem Cells Market is segmented into:
On the basis of region, the global Mesenchymal Stem Cells Market is segmented into: